Finance

Lists
I1DX34:BVMF
Idexx Laboratories Inc Bdr
R$516,36
0,00%
(0,00) 1D
9 Okt., 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for I1DX34...
Open
R$516,36
High
R$516,36
Low
R$516,36
Mkt. cap
40,81 mjd
Avg. vol.
6,00
Volume
5,00
52-wk high
R$813,60
52-wk low
R$509,99
Shares outstanding
78,78 m
No. of employees
11 k
Open
R$516,36
High
R$516,36
Low
R$516,36
Mkt. cap
40,81 mjd
Avg. vol.
6,00
Volume
5,00
52-wk high
R$813,60
52-wk low
R$509,99
Shares outstanding
78,78 m
No. of employees
11 k
News stories
From web sources and news partners
Profile
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs about 11,000 people in full-and part-time positions. In 2002, Jon Ayers succeeded company founder Shaw as chairman and CEO. During Ayers 20-year tenure, the company's annual revenue grew from $380 million to $3 billion, raising share prices by more than 100 times. In 2019, Jay Mazelsky succeeded Ayers in the role of CEO. In 2025, IDEXX estimated annual sales between $4.21 billion and $4.28 billion, with total quarterly revenue exceeding $1 billion. Wikipedia
About Idexx Laboratories Inc Bdr
CEOJay Mazelsky
Employees11 k
Founded19 Des. 1983
HeadquartersWestbrook, Maine, Verenigde State van Amerika
SectorMedical device
Websiteidexx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,11 mjd
1,09 mjd
1,14 mjd
1,22 mjd
Cost of goods sold
421,88 m
432,46 m
418,08 m
437,50 m
Cost of revenue
421,88 m
432,46 m
418,08 m
437,50 m
Research and development expenses
63,42 m
66,83 m
65,79 m
65,43 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
265,09 m
266,68 m
294,36 m
288,09 m
Operating expense
328,51 m
333,51 m
360,15 m
353,52 m
Total operating expenses
750,39 m
765,97 m
778,23 m
791,02 m
Operating income
354,85 m
324,60 m
362,59 m
425,57 m
Other non operating income
-
-
-
-
EBT including unusual items
344,77 m
306,98 m
355,44 m
417,22 m
EBT excluding unusual items
344,77 m
315,98 m
355,44 m
415,99 m
Income tax expense
70,16 m
58,79 m
77,00 m
78,81 m
Effective tax rate
20,35%
19,15%
21,66%
18,89%
Other operating expenses
-
-
-
-
Net income
274,61 m
248,19 m
278,45 m
338,41 m
Net profit margin
24,85%
22,76%
24,41%
27,82%
Earnings per share
3,40
3,08
3,47
4,27
Interest and investment income
580,00 k
587,00 k
597,00 k
606,00 k
Interest expense
-10,66 m
-9,21 m
-7,74 m
-10,18 m
Net interest expenses
-10,08 m
-8,62 m
-7,14 m
-9,58 m
Depreciation and amortization charges
-
-
-
-
EBITDA
391,47 m
363,33 m
400,27 m
466,62 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme